Human Bcl-2 antisense therapy for lymphomas

This publication has 27 references indexed in Scilit:

• Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
  Blood, 1998
• Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study
  Blood, 1996
• Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
  Journal of Clinical Oncology, 1996
• Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)
  Blood, 1996
• Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey
  Antisense Research and Development, 1994
• Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
  Proceedings of the National Academy of Sciences, 1991
• Substrate Specificity and Kinetics of Degradation of Antisense Oligonucleotides by a 3′ Exonuclease in Plasma
  Antisense Research and Development, 1991
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
  Nature, 1990
• Specific regulation of gene expression by antisense, sense and antigene nucleic acids
  Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1990
• Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.
  Proceedings of the National Academy of Sciences, 1988